Literature DB >> 10146997

Economic evaluation of drug therapy: a review of the contingent valuation method.

M Johannesson1, P O Johansson, B Jönsson.   

Abstract

The aim of this paper is to review the use of the contingent valuation (CV) method in economic evaluation of drug therapy. With the CV method, willingness to pay for a project 'treatment' is measured with survey methods, which makes it possible to carry out traditional cost-benefit analysis. The CV method has been developed in environmental economics and is now the most commonly used method of measuring environmental benefits. Due to the limitations of existing methods, empirical applications are starting to appear in the health field as well. From the empirical applications with respect to drug treatment it is evident that it is possible to achieve acceptable response rates. The methodological problems encountered when measuring willingness to pay with survey methods are similar to the problems encountered when measuring utility and quality of life in cost-utility analysis. It is concluded that further studies with the CV method are necessary to further explore questions concerning the reliability and validity of the method in this field.

Mesh:

Year:  1992        PMID: 10146997     DOI: 10.2165/00019053-199201050-00004

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  10 in total

1.  Addition of non-pharmacological methods of treatment in patients on antihypertensive drugs: results of previous medication, laboratory tests and life quality.

Authors:  H Aberg; G Tibblin
Journal:  J Intern Med       Date:  1989-07       Impact factor: 8.989

Review 2.  Economic evaluation in health care: is there a role for cost-benefit analysis?

Authors:  M Johannesson; B Jönsson
Journal:  Health Policy       Date:  1991-02       Impact factor: 2.980

3.  Economic evaluation of lipid lowering--a feasibility test of the contingent valuation approach.

Authors:  M Johannesson
Journal:  Health Policy       Date:  1992       Impact factor: 2.980

4.  Willingness to pay for antihypertensive therapy--results of a Swedish pilot study.

Authors:  M Johannesson; B Jönsson; L Borgquist
Journal:  J Health Econ       Date:  1991       Impact factor: 3.883

Review 5.  Cost-effectiveness analysis of hypertension treatment--a review of methodological issues.

Authors:  M Johannesson; B Jönsson
Journal:  Health Policy       Date:  1991-09       Impact factor: 2.980

6.  Willingness to pay and accept risks to cure chronic disease.

Authors:  M S Thompson
Journal:  Am J Public Health       Date:  1986-04       Impact factor: 9.308

7.  Economics of coronary artery bypass grafting.

Authors:  A Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1985-08-03

8.  The economic cost of illness revisited.

Authors:  B S Cooper; D P Rice
Journal:  Soc Secur Bull       Date:  1976-02

9.  Economic evaluation of neonatal intensive care of very-low-birth-weight infants.

Authors:  M H Boyle; G W Torrance; J C Sinclair; S P Horwood
Journal:  N Engl J Med       Date:  1983-06-02       Impact factor: 91.245

10.  Cost-benefit analysis of non-pharmacological treatment of hypertension.

Authors:  M Johannesson; H Aberg; L Agréus; L Borgquist; B Jönsson
Journal:  J Intern Med       Date:  1991-10       Impact factor: 8.989

  10 in total
  7 in total

1.  Defining monetary values for quality of life improvements: an exploratory study.

Authors:  Jean Lachaine; Claudine Laurier; André-Pierre Contandriopoulos
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

2.  The Australian Guidelines for subsidisation of pharmaceuticals: the road to cost-effective drug prescribing?

Authors:  M Johannesson
Journal:  Pharmacoeconomics       Date:  1992-11       Impact factor: 4.981

3.  Drug expenditure and new drug introductions: the Swedish experience.

Authors:  U G Gerdtham; M Johannesson; B Jönsson
Journal:  Pharmacoeconomics       Date:  1993-09       Impact factor: 4.981

4.  Methodological and conduct principles for pharmacoeconomic research. Pharmaceutical Research and Manufacturers of America.

Authors:  K Clemens; R Townsend; F Luscombe; J Mauskopf; J Osterhaus; J Bobula
Journal:  Pharmacoeconomics       Date:  1995-08       Impact factor: 4.981

Review 5.  Insulin lispro: a pharmacoeconomic review of its use in diabetes mellitus.

Authors:  Christopher J Dunn; Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

6.  A review of cost-effectiveness analyses of hypertension treatment.

Authors:  M Johannesson; B Jönsson
Journal:  Pharmacoeconomics       Date:  1992-04       Impact factor: 4.981

7.  Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem.

Authors:  A Gafni; S Birch
Journal:  CMAJ       Date:  1993-03-15       Impact factor: 8.262

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.